SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.

A SPAC III Acquisition Corp. - Ordinary Shares - Class A

Alpha Capital Acquisition Co - Ordinary Shares - Class A

ASPC is trending due to extreme price volatility and massive trading volume, fueled by speculation around its low float and high borrow rate. The community is actively debating a potential short squeeze, comparing its wild swings to past parabolic runners, while others warn of a pump and dump scenario, highlighting its nature as a high-risk SPAC play.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp (OMER) is trending following the recent FDA approval of YARTEMLEA, its first-in-class treatment for transplant-associated thrombotic microangiopathy, addressing a severe condition with no current alternatives. The community is actively discussing the significant revenue potential from this market monopoly and the company's strengthened financial position due to a major partnership and debt reduction. Investors are keenly awaiting the upcoming conference call for further commercialization details and potential additional catalysts.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU CRYPTO is trending due to its exceptionally active and dedicated community, which consistently emphasizes strong conviction and relentless real-world brand building. Discussions highlight ongoing initiatives to launch diverse IRL products and ventures, such as energy drinks, merchandise, and a spice brand. This positions KENDU as a unique decentralized brand focused on long-term growth and an expanding global presence.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is trending as traders navigate expectations of a year-end rally and anticipated Federal Reserve rate cuts, driving significant bullish speculation in the tech-heavy Nasdaq. The recent 2-for-1 stock split has sparked community debate, with many seeing it as a potential catalyst for renewed buying interest, while others express caution regarding amplified market volatility and the long-term sustainability of the AI-driven rally. Sentiment remains divided, balancing aggressive upside bets against concerns over leveraged exposure in a dynamic market.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust ($SLV) is experiencing a significant surge, driven by escalating concerns over diminishing global supply, particularly with China's impending silver export restrictions, meeting heightened industrial demand for critical technologies. This price action has ignited intense debate among investors, with bulls celebrating a potential 'silver squeeze' and a long-overdue revaluation of the metal, while bears warn of a parabolic 'blow-off top' and an imminent correction.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. It offers Alpha, Beta, Gamma, and orbital transfer vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 27, 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace is trending following recent strong earnings and strategic moves, including an acquisition that expands its defense capabilities, driving renewed optimism. The community is actively debating its valuation after a significant post-IPO pullback, with many anticipating future catalysts from upcoming launches and potential lucrative government contracts within the burgeoning space sector.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is making significant waves in the cybersecurity landscape, driven by an expanded multi-year partnership with Google Cloud focused on AI security and recent strategic acquisitions. The community is buzzing with discussions on its long-term growth potential in a booming sector, even as some traders evaluate recent price movements as a compelling buy-the-dip opportunity for this platform leader.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending due to strong Black Friday-Cyber Monday sales figures and robust recent earnings, showcasing impressive growth in merchant solutions and gross merchandise volume. The community is actively discussing its expanding AI ecosystem and strategic positioning within the e-commerce sector, anticipating continued momentum through the holiday season.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

AIRCOIN is trending amidst strong community adoption of its innovative "AirLock" initiative, which has led to a significant portion of the token's supply being locked up by holders. This focus on "community-owned supply control" is generating widespread bullish sentiment, with many believing it marks a revolutionary approach for memecoins on Solana and anticipate substantial future movement.

Polestar Automotive Holding UK Plc is the Swedish electric performance car brand that engages in the research, development, marketing, commercialization, and sales of battery electric vehicles and related technology solutions. It offers Polestar 2 (PS2), a premium fast-back sedan, the Polestar 3 (PS3), a luxury aero sport-utility vehicle, the Polestar 4 (PS4), a premium sport utility vehicle, the Polestar 5 (PS5), a luxury sport grand-touring sedan, and the Polestar 6 (PS6), a luxury roadster. The company was founded on September 15, 2021 and is headquartered in Gothenburg, Sweden.

Polestar Automotive Holding UK PLC - ADR Class A

Polestar is a key trending topic following a significant $600 million financing injection and a substantial 1-for-30 reverse stock split. While the financing aims to bolster its financial position, the community is vocally divided, with many seeing the reverse split as a tactic masking deeper concerns about dilution, cash burn, and management's ability to drive profitability in the challenging EV landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Quoin is now looking to move forward with the manufacture of clinical trial and stability batches from at least one of the delivery technologies this quarter.</li><li>The company is looking to test the technologies in the treatment of microcystic lymphatic malformations and venous malformations, among others.</li><li>The company is targeting the commencement of clinical testing in the first half of 2026. &nbsp;</li></ul>&nbsp;Shares of Quoin Pharmaceuticals (QNRX) jumped as much as 39% on Tuesday after the company announced that the target loading concentrations for its two topical Rapamycin delivery technologies have been successfully achieved.A Rapamycin loading concentration of 4% w/w has been achieved for Quoin’s topical formulation, while an even higher concentration of 5% w/w has been formulated in a dermal patch system, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/11/3185408/0/en/Quoin-Pharmaceuticals-Announces-Achievement-of-Topical-Rapamycin-Target-Loadings-for-Two-Proprietary-Delivery-Technologies.html">said</a>.<h2 class="st-heading-2">Path Forward</h2>Quoin is now looking to move forward with the manufacture of clinical trial and stability batches from at least one of the delivery technologies this quarter. The company is targeting the commencement of clinical testing in the first half of 2026. &nbsp;The company is looking to test the technologies in the treatment of microcystic lymphatic malformations and venous malformations, among others. Microcystic lymphatic malformations are benign vascular anomalies characterized by a collection of small, abnormal lymphatic vessels and cysts, often appearing as small, skin-colored to pinkish or even dark, blister-like vesicles on the skin.Venous malformations, meanwhile, are present at birth, but not always visible, and are the most common type of vascular malformation. They are caused by veins that have not developed normally, resulting in tangled, enlarged vessels. Symptoms can include bluish or purplish spots, swelling, and pain.Neither microcystic lymphatic malformations nor venous malformations have FDA-approved treatments.<h2 class="st-heading-2">Executive Take Away</h2>According to Quoin CEO Michael Myers, initiating clinical development in microcystic lymphatic malformations and venous malformations will be complementary to the company’s pipeline.The firm is now looking forward to the commencement of pivotal studies for QRX003 in Netherton Syndrome by the end of the year, with the help of the financing of up to $105.3 million closed in October. Quoin’s overall pipeline comprises four products in development for Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, and Scleroderma, among others.<blockquote>“We believe that rapamycin loading concentrations of 4% and 5% in these proprietary delivery systems could potentially provide competitive advantages over other topical rapamycin formulations currently in development with similar drug loadings due to the ability of our technologies to optimize delivery of the drug at the target sites.” &nbsp; - Michael Myers, CEO, Quoin.</blockquote><h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/QNRX">QNRX stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.QNRX stock is down by 59% this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/chamath-palihapitiya-talks-about-us-achilles-heel-when-it-comes-to-rare-earths/cLPdHr9REPH">Chamath Palihapitiya Talks About US' Achilles Heel When It Comes To Rare Earths</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

QNRX Stock Soared A Whopping 39% Today: What’s Driving The Relentless Rally? 

A rapamycin loading concentration of 4% w/w has been achieved for Quoin’s topical formulation, while an even higher concentration of 5% w/w has been formulated in a dermal patch system, the company said.

Equity

Quoin Pharmaceuticals (QNRX) became the top-four trending ticker on Stocktwits on Friday morning after the stock jumped nearly 300% after the company announced that it has entered into a securities purchase agreement with new healthcare-focused institutional investors, with the potential to raise $104.5 million in gross proceeds.The late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases said that this purchase agreement also includes an initial upfront funding of $16.5 million and up to an additional $88 million upon the potential cash exercise of accompanying warrants at the election of the investors.The firm added that&nbsp;the private placement was priced at a premium to the company’s prior day’s closing stock price. Quoin said that the financing includes participation from new healthcare-focused investors, including AIGH Capital Management, Soleus Capital, Nantahala Capital, Diadema Partners, Stonepine Capital Management, ADAR1 Capital Management, and Velan Capital, among others.Retail sentiment on <a href="https://stocktwits.com/symbol/QNRX">Quoin</a> jumped to ‘extremely bullish’ from ‘bearish’ territory compared to a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.Quoin said it will issue an aggregate of 1,993,940 American Depository Shares (ADSs) and accompanying warrants to purchase up to an aggregate of 7,975,760 ADSs, at a combined purchase price of $8.25 per ADS and accompanying warrants.The company said it intends to use the upfront net proceeds for general corporate purposes, which may include operating expenses, research and development, including completion of clinical development of QRX003 for Netherton Syndrome, working capital, future acquisitions, and general capital expenditures.&nbsp;The aggregate net proceeds are expected to be sufficient to fund the company into 2027. Shares of Quoin have gained nearly 41% this year and have jumped 76% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/kalshi-doubles-valuation-to-5-b-in-latest-funding-round-report/ch6aClnR3SM">Kalshi Doubles Valuation To $5B In Latest Funding Round: Report</a>

QNRX Stock Soars 300% After $104.5M Financing Through Private Placement

Quoin said that the purchase agreement also includes an initial upfront funding of $16.5 million and up to an additional $88 million upon the potential cash exercise of accompanying warrants at the election of the investors.

Shares of Quoin Pharmaceuticals saw increased retail chatter on Wednesday after the company announced positive initial clinical data from its ongoing investigational new drug Pediatric Peeling Skin Syndrome (PSS) study evaluating QRX003.Twelve weeks of treatment produced a clear improvement in the patient's skin condition compared to initial baseline measurements.&nbsp;The stock closed at $7.65 on Wednesday, rising 20.3% during the day, but slipped 8% to $7.04 in after-hours trading.Clinical endpoints such as The Investigator's Global Assessment (IGA), Modified Ichthyosis Area Severity Index (M-IASI), and Children's Dermatology Life Quality Index (CDLQI) showed positive changes.&nbsp;The patient's IGA score changed from severe to mild, M-IASI decreased from 36 to 12, and CDLQI, the quality of life measure, fell from 19 to 11. The study reported no adverse events while administering QRX003 to patients.Quoin will extend the patient's treatment while performing additional clinical evaluations after 24 weeks of therapy.&nbsp;The firm continues to progress QRX003 through late-stage clinical trials targeting Netherton Syndrome, another uncommon skin condition.Peeling Skin Syndrome is a rare genetic disorder that manifests through excessive outer skin shedding, leading to persistent pain and itching.&nbsp;Without any existing approved treatments, the promising results from QRX003 trials suggest its potential importance if future studies confirm the positive outcomes.CEO Michael Myers stressed the clinical importance of observed improvements and pointed out QRX003's potential to become the first approved therapy for PSS, noting plans to expand the study internationally.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 2,314% surge in 24-hour message volume.One user noted that some investors with less conviction tend to sell just before market close, expressing hope that the stock would open at $20.&nbsp;<stembedurl>https://stocktwits.com/89gt/message/614698425</stembedurl>Another user highlighted the stock’s potential for rapid movement due to its very low float and recent positive news.<stembedurl>https://stocktwits.com/MasterofThePennies/message/614637863</stembedurl>The stock has declined 67.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Buzz Intensifies Around Quoin Pharma Stock After Positive Pediatric Skin Study Data

The stock closed up 20% on Wednesday, driven by promising patient outcomes and no reported adverse events for its Pediatric Peeling Skin Syndrome (PSS) drug, with further treatment and evaluations planned.

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

QNRX
Quoin Pharmaceuticals Ltd - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest QNRX News

QNRXQuoin Pharmaceuticals Ltd - ADR